Dizal Pharma is Wuxi's first home-grown biopharmaceutical company. [Photo/WeChat account: xinwu_wx]

Dizal Pharma, based in Wuxi National Hi-tech District (WND), is establishing itself as a leading example of how Chinese biotech companies can compete on a worldwide scale. Focusing on innovative treatments for cancer and immune disorders, the company is reshaping China's influence in international drug development.

Founded in 2017 and spun off from AstraZeneca's translational science center for oncology, Dizal has embraced globalization from the start. "Our global competitiveness is built on three pillars: identifying unmet medical needs, focusing on differentiated and high-potential areas, and building strong technical barriers," said Zhang Xiaolin, chairman and CEO of Dizal.

Sunvozertinib is developed by Dizal Pharma. [Photo/WeChat account: xinwu_wx]

This vision has already produced results. Dizal's leading product, sunvozertinib, recently became the first drug of China origin and independent development to earn FDA approval for treating a rare form of non-small cell lung cancer.

The company emphasizes initiating all drug pipelines with synchronized international clinical trials, frequently collaborating with global research centers and top experts. This approach speeds up regulatory approvals worldwide and enhances the company's reputation in the global scientific community.

Supported by a cutting-edge platform for molecular design and translational science, Dizal has developed seven drug candidates that are competitive on a global scale.

On June 27, Dizal secured a strategic investment of 120 million yuan ($16.72 million) from the Wuxi Biomedicine Industry Fund, strengthening local backing for its global goals.